Evidence map›Paper›PMID 40812775›Full record

Trial reportNano letters2025

Chemical vs Physical Radioenhancement from TiO

Lukas R H Gerken, Laurin G S Schaller, Robert Nißler, Sebastian Habermann, Claire Beckers, Maximilian Dommke, Simon Heinze, Martin Pruschy, Ludwig Plasswilm, Inge K Herrmann

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lukas R H GerkenNanomaterials in Health Laboratory, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.ORCID 0000-0002-8568-2674
Laurin G S SchallerNanomaterials in Health Laboratory, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.
Robert NißlerNanomaterials in Health Laboratory, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.
Sebastian HabermannNanomaterials in Health Laboratory, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.
Claire BeckersLaboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Maximilian DommkeFraunhofer IKTS, Fraunhofer Institute for Ceramic Technologies and Systems, Michael-Faraday-Straße 1, Hermsdorf 07629, Germany.
Simon HeinzeDepartment of Radiation Oncology, Cantonal Hospital St. Gallen (KSSG), Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland.
Martin PruschyLaboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Ludwig PlasswilmDepartment of Radiation Oncology, Cantonal Hospital St. Gallen (KSSG), Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland.
Inge K HerrmannNanomaterials in Health Laboratory, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.ORCID 0000-0002-3018-6796

Funding

ETH GrantKrebsligaSwiss National Science Foundation
6 · The paper itself

Abstract

Hypoxia, a common feature in solid tumors, induces cellular radioresistance and reduces radiotherapy efficacy. Nanoparticles present a promising radiosensitizing approach providing localized dose enhancement through physical or chemical mechanisms. While many preclinical studies have shown nanoparticle radiosensitization, most have focused on normoxic conditions, leaving the impact of hypoxia on nanoparticle-mediated dose enhancement unclear. Here, we report on physical and chemical dose enhancement of Au and TiO

Indexed as

FibrosarcomaGoldMetal NanoparticlesRadiation-Sensitizing AgentsRadiation ToleranceTitaniumCell HypoxiaCell Line, TumorDNA DamageHumansReactive Oxygen SpeciesX-RaysX-Ray TherapyGoldRadiation-Sensitizing AgentsReactive Oxygen SpeciesTitaniumtitanium dioxideKilovoltageMegavoltagePhotocatalyticRadiocatalyticRadiosensitizerROS

Identifiers

PMID40812775
PMCPMC12395472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.